(IN BRIEF) Researchers at The Institute of Cancer Research, London, working with Merck KGaA, have developed the first potent small-molecule inhibitors of DHX8, an enzyme involved in pre-mRNA splicing. The compounds are described as “pathfinder molecules” rather than drug candidates, … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biochemical tests, cancer biology, cancer diversity, Cancer Drug Discovery, cancer evolution, Cancer Research UK, cancer stress responses, cancer-selective therapeutic window, Centre for Cancer Drug Discovery, chemical probes, compound 53, crystal structure, DEAH-box RNA helicases, DHX8, Dr Rob van Montfort, drug resistance, fragment-based drug design, gene expression, hard-to-drug targets, helicase domain, Hit Discovery and Structural Design Group, HSF1, ICR, ICR and Merck KGaA Advance Fragment-Based Approach to Target DHX8, Journal of Medicinal Chemistry, lung cancer cells, Medicinal Chemistry, Merck KGaA, mRNA splicing, nanomolar concentrations, New Small-Molecule Inhibitors Open Route to Underexplored RNA Helicase Cancer Targets, oncogenes, pathfinder molecules, Pathfinder Molecules Show Potential to Unlock New Family of Cancer Drug Targets, pre-mRNA splicing, protein translation, RNA binding, RNA helicase family, RNA processing, RNA-competitive inhibitors, small molecule inhibitors, spliceosome, structural biology, structure-guided medicinal chemistry, target engagement, The Institute of Cancer Research London, therapeutic cancer targets, underexploited drug targets, X-ray crystallography
(IN BRIEF) A new study led through collaboration between The Institute of Cancer Research, the Karolinska Institute, and Uppsala University has found that some cases of iAMP21, a rare high-risk subtype of paediatric acute lymphoblastic leukaemia, may begin before birth. … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged all®, bone marrow, cancer evolution, Center for Medical Mass Screening in Sweden, childhood cancer research, childhood leukaemia, chromosome 21 amplification, clonal evolution, Dr Gustaf Leijonhufvud, Dr Tony Ford, Dr Viktor Ljungström, Early Detection, genetic alterations, genetic rearrangement, Haematologica, heel prick tests, high-risk leukaemia, iAMP21, ICR, intrachromosomal amplification of chromosome 21, Karolinska Institute, Karolinska University Hospital, London, lymphocytes, May 26 2026, neonatal blood spots, New ICR-Led Research Traces Early Genetic Origins of High-Risk Childhood Leukaemia to Neonatal Blood Samples, New Study Shows Neonatal Blood Spots Can Reveal Early Genetic Alterations Associated with iAMP21 Leukaemia, paediatric acute lymphoblastic leukaemia, paediatric cancer, pre-ALL clone, pre-leukaemic changes, prenatal origins, Professor Britt Gustafsson, Professor Sir Mel Greaves, Researchers Uncover Evidence That Rare Childhood Leukaemia Subtype Can Begin Years Before Diagnosis, Sweden, Swedish Childhood Cancer Society, The Institute of Cancer Research, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype Can Begin Before Birth, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype May Originate Before Birth, United Kingdom, Uppsala University
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?